Skip to content
  • Report Harm
  • Newsletter
  • Press Room
Facebook Linkedin YouTube Instagram Twitter Spotify
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • VolunteerExpand
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our ImpactExpand
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • ResourcesExpand
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Donate
Facebook Linkedin Twitter Instagram YouTube
Benzodiazepine Information Coalition

Benzodiazepines and PTSD

Benzodiazepines like Valium, Ativan, Klonopin and Xanax are often prescribed off-label, against nearly all guidelines for patients with PTSD and C-PTSD. 

Benzodiazepines lack efficacy for PTSD

A 2014 systematic review and meta-analysis, and at least 1 measure in every study that was reviewed in the meta-analysis (including 4 Randomized Clinical Trials of benzodiazepines in PTSD), suggest a lack of efficacy for PTSD. 

The meta-analysis states:

PTSD-specific measures that were used demonstrated that benzodiazepines are, at
best, not significantly different from placebo or no benzodiazepine for PTSD.

The likely explanation for these findings is the development of tolerance to the effects of the drug, as well as the adverse cognitive effects associated with benzodiazepines. The findings also indicate that benzodiazepines appear to inadequately target PTSD pathophysiology, which could be another reason for their ineffectiveness.

Every available PTSD practice guideline supports benzodiazepine inefficacy in PTSD.

Benzodiazepines worsen the severity and prognosis of PTSD

In the same systematic review and meta-analysis, thirteen of the studies that were reviewed (including 2 Randomized Clinical Trials), several practice guidelines and some case reports suggested that benzodiazepines carry the risk of worsening the severity and prognosis of PTSD. 

The meta-analysis states:

All but 2 of the 13 studies that used PTSD specific measures demonstrated that benzodiazepines are associated with worse overall severity of symptoms when compared with placebo or no benzodiazepine.

These researchers also found that people who had recently gone through traumatic experiences were two to five times more likely to develop PTSD if given benzodiazepines. 

Evidence-based trauma-focused psychotherapies (e.g., prolonged exposure therapy) are the first-line of treatment for PTSD. These therapies require that patients be able to fully experience the PTSD-related anxiety in order to overcome it. When prescribed benzodiazepines, that ability to experience is impaired as the medications can cause emotional anesthesia, cognitive impairments resulting in decreased learning efficacy, and memory impairment which interferes with processing of the material learned in therapy.

Yet they’re still being prescribed in large numbers…

Credit: Wikimedia Commons

Prescribing clinicians at The Department of Veteran’s Affairs are continuing to ignore guidelines and prescribe benzodiazepines to veterans diagnosed with post-traumatic stress disorder despite VA guidelines advising against their use for the condition. These guidelines state that benzodiazepines are not to be used as monotherapy or adjunctively for PTSD.

Veterans aren’t the only individuals diagnosed with PTSD, however, as civilians sometimes experience traumatic events too; also often being prescribed benzodiazepines by their GP or psychiatrist. Almost 1/3 of veterans with a PTSD label are prescribed benzodiazepines. In the United States, benzodiazepines are estimated to be prescribed to 30-74% of patients with PTSD. This prescribing is often done without any informed consent  as to the risks and dangers of long-term benzodiazepine prescription, even when used as directed.

The available evidence makes clear that benzodiazepines alone are being negligently prescribed for diagnoses of PTSD in the military (and in civilians). An even more alarming trend, however, is when benzodiazepines are used as one agent in polypharmacy for servicemen and women. Sometimes this polypharmacy causes sudden cardiac death (SCD) in otherwise young, previously healthy soldiers. In an explosive letter published in the European Heart Journal, Dr. Fred Baughman  investigated the cases of four American soldiers who died in their sleep, in 2008.

Baughman writes:

…all in their twenties…no signs of suicide or of a multi-drug ‘overdose’…as claimed by the Inspector General of the VA…All were on the same prescribed drug cocktail, Seroquel (antipsychotic), Paxil (antidepressant) and Klonopin (benzodiazepine) [emphasis added].

Baughman’s initial inquiry suggests as many as 247 soldiers have died from cardiac arrest after ingesting these drugs.

The US Department of Veterans Affairs shared that their benzodiazepine prescriptions for for VA PTSD patients decreased from 30% in 2012 to 9.1% in 2020. While this is a win for patient safety, the VAs benzodiazepine cessation guidelines are dangerously fast, with oversized reductions, potentially harming physically dependent veterans.

For more information on benzodiazepines and PTSD:

Benzodiazepines are Contraindicated in Post Traumatic Stress Disorder (PTSD)

Sedatives still used in PTSD despite warnings 

Benzodiazepines Ineffective, Possibly Harmful for PTSD

Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis

Contact Us

Inquiries
bic@benzoinfo.com

As an awareness organization, we do not offer any support services or guidance. See our resources for services and support.

Mailing Address
1042 Ft. Union Blvd, PMB 1030
Midvale, Utah 84047

Support BIC

We were formed to change the lack of knowledge in the public and the medical system. But we cannot do it alone. We rely solely on donations to operate. We are a 501(c)(3) tax exempt organization.

DONATE

Newsletter

Get notified about the latest studies, updates, calls to action, media stories, and other information.

*

IMPORTANT: After signing up, check your email to confirm we have the correct address. If you do not see an email, check your spam. We will add you to our newsletter once you complete this step to ensure delivery.

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Privacy Policy
Medical Disclaimer
Terms and Conditions
Free Charity Hosting by Kualo

Facebook Linkedin YouTube Instagram Twitter Spotify

© 2023 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our Impact
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • Resources
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Search
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset